Got Doxy- 'Flipping the Script' on STI PEP
Start Date
10/13/2025
Completion Date
4/13/2029
Summary
This study is being done to test the effects of doxycycline on inflammation and the bacteria in the body in people with HIV and in people on HIV pre-exposure prophylaxis. This drug is approved by the Food and Drug Administration (FDA) for the treatment of bacterial infections. The study team will investigate whether the drug has additional effects on inflammation or on the bacteria that live in the body.
Detailed Description
This project aims to determine the potential anti-inflammatory and microbiome effects of doxycycline when used as post-exposure prophylaxis (Doxy PEP) for sexually transmitted infections (STIs). This study is important in the field of research because it allows the investigators to define the systemic and gut anti-inflammatory, microbiome, and resistome effects of doxycycline when used as post-exposure prophylaxis (Doxy PEP) for sexually transmitted infections. The study population that this study seeks to enroll consists of healthy people assigned male at birth, with and without HIV, who are willing to undergo study procedures. Study procedures will include the collection of medical history, as well as biological specimen sampling, such as blood and rectal tissue biopsies. The duration of this clinical trial for study participants will be approximately 12 weeks. This will include five in-person visits lasting about 45 minutes to 1 hour (including two biopsy visits). This study will utilize data specimen banking for future research.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Doxycycline monohydrate 200 mg
Observation
Conditions
Locations
Grady Health System (non-CRN)
Atlanta, Georgia 30322
United States
Hope Clinic
Atlanta, Georgia 30322
United States